Linear cyclodextrin-containing polymers and their use as delivery agents

Expert Opinion on Drug Delivery

Volumn 3, Issue 5, 2006, Pages 641-646

  Heidel, Jeremy D ^a  

^a Calando Pharmaceuticals   (United States)

Author keywords

Camptothecin; Cyclodextrins; Nucleic acid delivery; Polymers; siRNA; Small molecule delivery

Indexed keywords

ADAMANTANE; ANTINEOPLASTIC AGENT; BETA CYCLODEXTRIN; CAMPTOTHECIN; CHITOSAN; COPOLYMER; CYCLODEXTRIN; CYCLODEXTRIN DERIVATIVE; DENDRIMER; GALACTOSE; IRINOTECAN; IT 101; MACROGOL; MERCAPTAMINE; NUCLEIC ACID; ORGANIC COMPOUND; POLYETHYLENEIMINE; POLYLYSINE; POLYMER; SMALL INTERFERING RNA; TOPOTECAN; TRANSFERRIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BIOCOMPATIBILITY; CANCER; CHEMICAL MODIFICATION; CLINICAL TRIAL; COMPLEX FORMATION; DNA DRUG COMPLEX; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG UPTAKE; GENE THERAPY; HUMAN; IC 50; MAXIMUM TOLERATED DOSE; MOLECULAR INTERACTION; MOLECULAR WEIGHT; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OPTIMAL DRUG DOSE; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

CAMPTOTHECIN; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; DNA; DRUG DELIVERY SYSTEMS; POLYMERS; RNA, SMALL INTERFERING;

EID: 33748636431     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.3.5.641     Document Type: Review

References (34)

1. DAVIS ME, BREWSTER ME: Cyclodextrin-based pharmaceutics: past, present, and future. Nat. Rev. Drug Deliv. (2004) 3:1023-1035.
2. MA M, LI D: New organic nanoporous polymers and their inclusion complexes. Chem. Mater. (1999) 11:872-874.
3. NEWKOME GR, GODINEZ LA, MOOREFIELD CN: Molecular recognition using β-cyclodextrin-modified dendrimers: novel building blocks for convergent self-assembly. Chem. Commun. (1998):1821-1822.
4. VICENT MJ, DUNCAN R: Polymer conjugates: nanosized medicines for creating cancer. Trends Biotechnol. (2006) 24:39-47.
5. MATSUMURA Y, MADEA H: A new concept for macromolecular therapeutics in cancer-chemotherapy: mechanism of tumoritropic accumulation of protein and the antitumor agent SMANCS. Cancer Res. (1986) 6:6387-6392.
6. MIYAMOTO Y, ODA T, MAEDA H: Comparison of the cytotoxic effects of the high- and low-molecular-weight anticancer agents on multidrug-resistant Chinese hamster ovary cells in vitro. Cancer Res. (1990) 50:1571-1575.
7. CREAVEN PJ, ALLEN LM, MUGGIA FM: Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chemother. Rep. (1972) 56:573-578.
8. MUGGIA FM, CREAVEN PJ, HANSEN HH et al: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother. Rep. (1972) 56:515-521.
9. CONOVER CD, GREENWALD RB, PENDRI A et al: Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs. Anticancer Drug Des. (1999) 14:499-506.
10. BHATT R, DE VRIES P, TULINSKY J et al.: Synthesis and in vivo antitumor activity of poly(L-glutamic acid) conjugates of 20S-captothecin. J. Med Chem. (2003) 46:190-193.
11. CHENG J, KHIN KT, JENSEN GS et al: Synthesis of linear, β-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjug. Chem. (2003) 14:1007-1017.
12. CHENG J, KHIN KT, DAVIS ME: Antitumor activity of β-cyclodextrin polymer-camptothecin conjugates. Mol. Pharm. (2004) 1:183-193.
13. SCHLUEP T, CHENG J, KHIN KT et al: Pharmacokinetics and biodisrribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother. Pharmacol. (2006) 57:654-662.
14. SCHLUEP T, HWANG J, CHENG J et al: Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin. Cancer Res. 2006) 12:1606-1614.
15. GONZALEZ H, HWANG SJ, DAVIS ME: New class of polymers for the delivery of macromolecular therapeutics. Bioconjug Chem. (1999) 10:1068-1074.
16. HWANG SJ, BELLOCQ NC, DAVIS ME: Effects of structure of β-cyclodextrin-containing polymers on gene delivery. Bioconjug. Chem. (2001) 12:280-290.
17. REINEKE TM, DAVIS ME: Structural effects of carbohydrate-containing polycations on gene delivery. 1. Carbohydrate size and its distance from charge centers. Bioconjug. Chem. (2003) 14:247-254.
18. REINEKE TM, DAVIS ME: Structural effects of carbohydrate-containing polycations on gene delivery. 2. Charge center type. Bioconjug. Chem. (2003) 14:255-261.
19. POPIELARSKI SR, MISHRA S, DAVIS ME: Structural effects of carbohydrate-containing polycations on gene delivery. 3. Cyclodextrin type and functionalization. Bioconjug. Chem. (2003) 14:247-254.
20. ERBACHER P, BETTINGER T, BELGUISE-VALLADIER T et al: Transfection and physical properties of various saccharide, poly(ethylene glycol), and antibody-derivatized polethyleneimines (PEI). J. Gene Med (1999) 1:210-222.
21. CHOI Y, LIU F, KIM J-S et al: Poly(ethylene glycol)-grafted poly-L-lysine as polymeric gene carrier. J. Control. Release (1998) 54:49-58.
22. PUN SH, DAVIS ME: Development of a nonviral gene delivery vehicle for systemic application. Bioconjug. Chem. (2002) 13:630-639.
23. DAVIS ME, BELLOCQ NC: Cyclodextrin-containing polymers for gene delivery. J. Incl. Phenom. (2002) 44:17-22.
24. MIDOUX P, MENDES C, LEGRAND A et al: Specific gene transfer mediated by lactosylated poly-L-lysine into hepatoma cells. Nucl. Acids Res. (2002) 21:871-878.
25. LIM D, YEOM Y, PARK T: Poly(DMAEMA-NVP)-b-PEG-galactose as gene delivery vector for hepatocytes. Bioconjug. Chem. (2000) 11:688-695.
26. BELLOCQ NC, PUN SH, JENSEN GS et al: Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug. Chem. (2003) 14:1122-1132.
27. PUN SH, TACK F, BELLOCQ NC et al: Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-targeted, cyclodextrin-based particles. Cancer Biol. Ther. (2004) 3:641-650.
28. MISHRA S, WEBSTER P, DAVIS ME: PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur. J. Cell. Biol. (2004) 83:97-111.
29. PACK DW, PUTNAM D, LANGER R: Design of imidazole-containing endosomolytic biopolymers for gene delivery. Biotechnol. Bioeng. (2000) 67:217-223.
30. AKINC A, THOMAS M, KLIBANOV AM et al: Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J. Gene Med. (2005) 7:657-663.
31. DAVIS ME, PUN SH, BELLOCQ NC et al: Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers. Curr. Med. Chem. (2004) 11:1241-1253.
32. KULKARNI RP, MISHRA S, FRASER SE et al: Single cell kinetics of intracellular nonviral, nucleic acid delivery vehicle acidification and trafficking. Bioconjug. Chem. (2005) 16:986-994.
33. MISHRA S, HEIDEL JD, WEBSTER P et al: End group imidazoles impart multiple effects on gene delivery of a linear, cyclodextrin-containing polycation. J. Control. Release (2006). In press.
34. HU-LIESKOVAN S, HEIDEL JD, BARTLETT DW et al: Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumors growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. (2005) 65:8984-8992.